Loading…
← CockpitCompetitor Analysis › 4528.T ONO Pharmaceutical Co., Ltd.Open in the cockpit ↗

ONO Pharmaceutical Co., Ltd.4528.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Pharmaceutical company that co-developed cancer drug Opdivo, earning royalties alongside its own drug pipeline.

≈ A specialty pharma with a blockbuster oncology royalty streamMomentum strong 62
Mkt cap
$7.33B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$31.1M
20-day average traded
Fwd P/E
15.3×
forward earnings
ROIC−WACC
+4.3 pp
WACC 5.9%
Hurdle
-18 pp
Req g minus delivered
Next earnings
75 days
1 Feb 2027
Close · JPY¥2,489
1D-0.1%
1W+2.7%
1M+2.2%
3M+2.4%
6M-1.8%
YTD+14.6%
1Y+30.5%
ATR %3.1%
52w lowhigh6.9% off high

What ONO Pharmaceutical does

Pharmaceutical company that co-developed cancer drug Opdivo, earning royalties alongside its own drug pipeline.

Sells Opdivo itself in Japan, South Korea and Taiwan and collects royalties on sales elsewhere, where Bristol Myers Squibb markets it. A patent settlement also brings royalties on Merck's rival drug Keytruda. Buying US drugmaker Deciphera in 2024 added cancer drugs that Ono now sells directly in the US.

In one line: A specialty pharma with a blockbuster oncology royalty stream.

Products and services

  • Opdivo (co-developed with BMS)
  • Other oncology drugs
  • Immunology/pain drugs

Customers

  • Hospitals/oncologists worldwide

Where it sits in the supply chain

  • Pharmaceuticals
  • Drug development & manufacturing
  • Oncology, immunology, pain therapeutics

What could go right

  • Opdivo royalty growth/new indications

What could go wrong

  • Opdivo patent cliff risk
  • Pipeline concentration

Moat: narrow (IP / patents). Patent-protected Opdivo royalty stream and pipeline in a high-value oncology franchise.

Headquarters: Osaka, Japan · Founded: 1717 · Employees: 4,206

Named competitors

ONO Pharmaceutical at a glance

Size ONO Pharmaceutical (4528.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $7.33B, the 181st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,489 on 18 Nov 2026.

Performance Over six months the shares fell 1.8%, against +5.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue fell 2.5% over the last twelve months (peer median +12.5%); the operating margin is 22.1% (peer median 13.7%).

Valuation It trades at 15.3× forward earnings against a peer median of 19.3× (7th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.3 points above its cost of capital (5.9% WACC).

Next results Next results expected around 1 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 1074528.T 102
Six months, rebased to 100: ONO Pharmaceutical against the median of its 20 peers (local-currency closes).

ONO Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥491B¥516B¥487B¥503B¥447B
Revenue growth—+6%-3%+12%—
Gross profit¥364B¥371B¥335B¥373B¥334B
EBITDA¥146B¥141B¥90.3B¥182B¥170B
Net income¥74.6B¥69.8B¥50.0B¥128B¥113B
Free cash flow¥127B¥131B¥77.0B¥107B¥154B
Capital expenditure¥11.8B¥53.3B¥7.99B¥20.8B¥14.5B
Total debt¥110B¥121B¥147B¥8.86B¥9.17B

Quarterly statements and history in the cockpit →

ONO Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-25%0%+25%002821CORTKNSAGRFCYTKIBRX600196BANBAMRX9926ALKSALK-BGLENMARK000963ALKEM000999RYTMORKA4528.T6-month return →1-month return →
Up and to the right = strong over both horizons. ONO Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×40×60×002821CORTKNSAGRF600196BANBAMRXALK-BGLENMARK000963ALKEM6016074528.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ONO Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%CORTKNSAGRF600196AMRXALKSALK-BGLENMARK000963ALKEM000999APTX6016074528.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ONO Pharmaceutical is the large dot.

ONO Pharmaceutical competitors and peer comparison

Head to head with its named competitors (4528.T vs BMY vs 4519.T vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
ONO Pharmaceutical 4528.T$7.33B-2%-2%22%15.3×-6.8%
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
Chugai Pharmaceutical 4519.T$75.2B-8%+17%50%23.7×5.0%
Merck & MRK$340B+23%+5%18%16.4×8.3%

How ONO Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ONO Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4528.TPeer medianRank in peer set
1-month return+2.2%+2.2%11th highest of 21
6-month return-1.8%+5.9%8th lowest of 20
Distance from 52-week high-6.9%-12.9%7th highest of 21
Revenue growth (TTM)-2.5%+12.5%lowest of 20
Operating margin22.1%13.7%3rd highest of 20
Forward P/E15.3×19.3×7th cheapest of 15
Growth the price implies (Req g, 7 yrs)-6.8%7.3%3rd least demanding of 14
Growth delivered (Del g)+10.8%+8.7%5th highest of 14
Hurdle (Req g minus delivered)-17.6 pp-3.7 pp4th least demanding of 14
ROIC minus cost of capital+4.3 pp+1.6 pp8th highest of 19
EV / EBITDA7.0×23.1×cheapest of 11
Net debt / EBITDA-1.0×0.8×3rd least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%14.8×2.9%+6.6%
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a

Questions

Who are ONO Pharmaceutical's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Chugai Pharmaceutical (4519.T), Merck & Co (MRK). The cockpit's measured peer set (industry) also includes Asymchem Laboratories (Tianjin) (002821.SZ), Corcept Therapeutics (CORT), Kiniksa Pharmaceuticals International (KNSA), Grifols (GRF.MC), Cytokinetics (CYTK), ImmunityBio (IBRX).
Is ONO Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 15.3× against a peer median of 19.3×, 7th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has ONO Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -1.8% against +5.9% for the median peer; over one year +30.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.